Locametz الاتحاد الأوروبي - الفنلندية - EMA (European Medicines Agency)

locametz

novartis europharm limited  - gozetotide - radionuklidien kuvantaminen - diagnostiset radiofarmaseuttiset valmisteet - tämä lääkevalmiste on tarkoitettu vain diagnostiseen käyttöön. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.

Pluvicto الاتحاد الأوروبي - الفنلندية - EMA (European Medicines Agency)

pluvicto

novartis europharm limited  - lutetium (177lu) vipivotide tetraxetan - eturauhasen kasvaimet, kastraatio-resistentin - terapeuttiset radiofarmaseuttiset valmisteet - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.

Aclasta الاتحاد الأوروبي - الفنلندية - EMA (European Medicines Agency)

aclasta

sandoz pharmaceuticals d.d. - zoledronihappoa - osteoporosis; osteitis deformans; osteoporosis, postmenopausal - lääkkeet luusairauksien hoitoon - treatment of osteoporosis: , in post-menopausal women;, in men; , at increased risk of fracture, including those with a recent low-trauma hip fracture. osteoporoosin hoito liittyy pitkän aikavälin systeeminen glukokortikoidi-hoito postmenopausaalisilla naisilla ja miehillä, joilla murtumariski on suurentunut. hoitoon pagetin tauti luu.

Adjupanrix (previously Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals) الاتحاد الأوروبي - الفنلندية - EMA (European Medicines Agency)

adjupanrix (previously pandemic influenza vaccine (h5n1) (split virion, inactivated, adjuvanted) glaxosmithkline biologicals)

glaxosmithkline biologicals s.a. - inaktivoitu, influenssavirus, joka sisältää antigeenia: a / vietnam / 1194/2004 (h5n1), kuten käytetty kanta (nibrg-14) - influenza, human; immunization; disease outbreaks - rokotteet - influenssan ennaltaehkäisy virallisesti ilmoitetussa pandemiatilanteessa. pandemian influenssarokote on käytettävä virallisten ohjeiden mukaisesti.